736992-21-5Relevant articles and documents
A novel mitochondria-targeting tetrapeptide for subcellular delivery of nanoparticles
Sun, Yanhui,Zhan, Aiyan,Zhou, Shuang,Kuang, Xiao,Shen, Hongyan,Liu, Hongzhuo,Xu, Youjun
, p. 1435 - 1439 (2019)
Mitochondrial dysfunction is associated with the emergence of several neurological and cardiovascular diseases. Hence, mitochondria-targeting delivery strategies are highly significant and critically needed. In this study, we developed a small library of peptides simulating the mitochondria-targeting peptide SS-31, a promising tetra-peptide with antioxidant character, and subsequently evaluated the toxicity, antioxidant ability and mitochondrial delivery of nanoparticles. Among the designed peptides, RF-2 (D-Arg-Dmt-Arg-Phe-NH2) showed controlled toxicity and excellent protection against gentamicin-induced hair cell damage, as compared with SS-31. More importantly, RF-2-modified PLGA nanoparticles demonstrated high colocalization with mitochondria and comparable specific subcellular accumulation, when compared with SS-31. Taken together, the obtained results supported RF-2 as a mitochondria-targeting peptide with high potential as a targeted carrier.
TETRAPEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME
-
Paragraph 0093; 0094, (2016/10/04)
The present invention is to provide a method for the efficient production on an industrial scale of SS-31 (D-Arg-Dmt-Lys-Phe-NH2), which is an SS peptide. According to the present invention, the desired SS-31 is produced by efficiently synthesizing a tetrapeptide compound as a precursor of SS-31 and improving the tetrapeptide purity by crystallization.